ARD103
ARD103 is a car-t cell therapy from ARCE Therapeutics, Inc., in registered phase 2 trials for acute myeloid leukaemia, myelodysplastic syndromes / neoplasms.
Overview
ARD103 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by ARCE Therapeutics, Inc., in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms. A chimeric antigen receptor T-cell therapy, as described in the registry record: the patient's T cells are engineered to recognise a tumour antigen and infused back. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A chimeric antigen receptor T-cell therapy, as described in the registry record: the patient's T cells are engineered to recognise a tumour antigen and infused back.
1.ARD103 slips into a pocket on its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"ARD103" OR ABSTRACT:"ARD103") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ARD103, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentBexmarilimab
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tags pipeline, registry-only.
- TrialFirst-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
- TrialPBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
- TreatmentSabatolimab
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tags pipeline, registry-only.
- TreatmentSpartalizumab
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tags pipeline, registry-only.
- TreatmentTuspetinib
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tags pipeline, registry-only.
- TreatmentRVU120
Shares Acute myeloid leukaemia and the tags pipeline, registry-only.